CTMX (STOCKS)
CytomX Therapeutics, Inc.
$4.390000
+0.000000 (+0.00%)
Prev close: $4.390000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sean A. McCarthy
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $946.86M
- Employees
- 121
- P/E (TTM)
- 482.42
- P/B (TTM)
- 7.55
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.22 | $-0.10 | -0.1245 | -130.37% |
|
Sep 2025 (Q3)
|
$-0.09 | $-0.05 | -0.0384 | -74.42% |
|
Jun 2025 (Q2)
|
$0.00 | $-0.08 | +0.0772 | +98.72% |
|
Mar 2025 (Q1)
|
$0.27 | $0.13 | +0.1435 | +113.44% |
Financial Statements
| Revenues | $76.20M |
| Benefits Costs and Expenses | $93.33M |
| Costs And Expenses | $93.33M |
| Operating Expenses | $98.57M |
| Research and Development | $68.73M |
| Other Operating Expenses | $29.84M |
| Operating Income/Loss | -$22.36M |
| Income/Loss From Continuing Operations After Tax | -$17.37M |
| Income/Loss From Continuing Operations Before Tax | -$17.13M |
| Income Tax Expense/Benefit | $238.00K |
| Income Tax Expense/Benefit, Current | $238.00K |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$17.37M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$17.37M |
| Net Income/Loss Available To Common Stockholders, Basic | -$20.37M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $3.00M |
| Preferred Stock Dividends And Other Adjustments | $3.00M |
| Basic Average Shares | 137,935,873 |
| Diluted Average Shares | 137,935,873 |
| Assets | $151.57M |
| Current Assets | $143.92M |
| Noncurrent Assets | $7.65M |
| Fixed Assets | $1.30M |
| Other Non-current Assets | $6.34M |
| Liabilities | $52.56M |
| Current Liabilities | $46.62M |
| Accounts Payable | $1.30M |
| Wages | $8.21M |
| Other Current Liabilities | $37.11M |
| Noncurrent Liabilities | $5.94M |
| Equity | $99.01M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $99.01M |
| Liabilities And Equity | $151.57M |
| Net Cash Flow From Operating Activities | -$75.59M |
| Net Cash Flow From Operating Activities, Continuing | -$75.59M |
| Net Cash Flow From Investing Activities | -$59.74M |
| Net Cash Flow From Investing Activities, Continuing | -$59.74M |
| Net Cash Flow From Financing Activities | $110.45M |
| Net Cash Flow From Financing Activities, Continuing | $110.45M |
| Net Cash Flow | -$24.89M |
| Net Cash Flow, Continuing | -$24.89M |
| Comprehensive Income/Loss | -$17.28M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$17.28M |
| Other Comprehensive Income/Loss | $84.00K |